CATXPerspective Therapeutics, Inc.
$2.71-22% 1Y
$2.71
$2.0552 weeks$5.65
Price
-22%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, a flag to check, the market undecided.
P/En/a
Market value$309.1M
1 year-22%
5 years-57%
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 9, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 8, 2026On October 8, 2026, Perspective Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration granted Fast Track Designation for the development of PSV359 for adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein-positive solitary fibrous …Other event · Form 8-K
- Oct 1, 2026On October 1, 2026, Perspective Therapeutics, Inc. updated its corporate presentation.Other event · Form 8-K
- Sep 14, 2026On September 14, 2026, Perspective Therapeutics, Inc. issued a press release announcing a clinical collaboration and supply agreement with Merck.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.